Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anastasios Stathis

Showing results (71-80 of 131) with videos related to

Pageof 14
Sort By:
Hematological Oncology|June 17, 2017
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutionsStefania Gobba, Alden A Moccia, Wiebke Gulden-Sala, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
Leukemia & Lymphoma|January 20, 2022
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemiaPanayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, et al.
Investigational New Drugs|September 1, 2019
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumorsMarkus Joerger, Anastasios Stathis, Yannis Metaxas, et al.
British Journal of Haematology|June 17, 2020
Pembrolizumab in relapsed or refractory Richter syndromePhilippe Armand, Niels Murawski, Daniel Molin, et al.
British Journal of Haematology|March 29, 2014
Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study GroupAnnarita Conconi, Markus Raderer, Silvia Franceschetti, et al.
British Journal of Haematology|June 28, 2017
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphomaElena Bernasconi, Eugenio Gaudio, Pascale Lejeune, et al.
Blood Advances|March 21, 2020
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic modelLuca Ceriani, Giuseppe Gritti, Luciano Cascione, et al.
Haematologica|August 5, 2018
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphomaAfua A Mensah, Luciano Cascione, Eugenio Gaudio, et al.
Blood|May 4, 2018
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphomaLuca Ceriani, Lisa Milan, Maurizio Martelli, et al.
Pageof 14

Showing results (71-80 of 131) with videos related to

Sort By:
Pageof 14
Hematological Oncology|June 17, 2017
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutionsStefania Gobba, Alden A Moccia, Wiebke Gulden-Sala, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
Leukemia & Lymphoma|January 20, 2022
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemiaPanayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, et al.
Investigational New Drugs|September 1, 2019
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumorsMarkus Joerger, Anastasios Stathis, Yannis Metaxas, et al.
British Journal of Haematology|June 17, 2020
Pembrolizumab in relapsed or refractory Richter syndromePhilippe Armand, Niels Murawski, Daniel Molin, et al.
British Journal of Haematology|March 29, 2014
Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study GroupAnnarita Conconi, Markus Raderer, Silvia Franceschetti, et al.
British Journal of Haematology|June 28, 2017
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphomaElena Bernasconi, Eugenio Gaudio, Pascale Lejeune, et al.
Blood Advances|March 21, 2020
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic modelLuca Ceriani, Giuseppe Gritti, Luciano Cascione, et al.
Haematologica|August 5, 2018
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphomaAfua A Mensah, Luciano Cascione, Eugenio Gaudio, et al.
Blood|May 4, 2018
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphomaLuca Ceriani, Lisa Milan, Maurizio Martelli, et al.
Pageof 14